Flagship VentureLabsTM co-founded Syros Pharmaceuticals with ARCH Venture Partners working with three world leaders within the field of gene regulation and translational medicine: Richard A. Young, Ph.D., Whitehead Institute, Massachusetts Institute of Technology; James “Jay” E. Bradner, M.D., Harvard Medical School, Dana Farber Cancer Institute, Broad Institute; and Nathanael Gray, Ph.D., Harvard Medical School, Dana Farber Cancer Institute. Syros is a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros’ proprietary platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics. Syros’ initial focus is in cancer, but the company platform will also be applicable to other therapeutic areas.
Doug Cole is on the Board of Directors.